<DOC>
	<DOCNO>NCT03053661</DOCNO>
	<brief_summary>The IRECT trial non-interventional , prospective clinical trial use modern immune monitoring technique course standard care HNSCC . The dynamic host/tumor immune interaction conventional standard treatment analyze find promising target antigen develop strategy specific immunotherapy add current treatment schedule . The result trial help understand state art treatment complement use cancer-testis antigen specific vaccine immune-modulating drug improve outcome head neck cancer patient .</brief_summary>
	<brief_title>Immune Response Evaluation Curative Conventional Therapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>newly diagnose patient stage IIIIVa/b head neck squamous cell carcinoma fit treatment curative intent conventional primary treatment primary surgical treatment primary radiotherapeutic treatment inform consent &gt; 18 year age sufficient contraception distant metastasis baseline severe concomitant disease compromise curative treatment previously diagnose malignant disease active immunosuppressive therapy know immune defect pregnancy anemia require treatment study entry ( &lt; 9g/dl )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Head Neck Squamous Cell Carcinoma</keyword>
	<keyword>cancer-specific immunity</keyword>
	<keyword>cancer immunology</keyword>
	<keyword>cancer-testis antigen</keyword>
	<keyword>human papilloma virus</keyword>
	<keyword>immune modulatory cell</keyword>
</DOC>